Recent clinical trials with menin inhibitors show promising results against MLL-rearranged (MLLr) AML, although resistance frequently occurs, rendering the menin-MLL interaction insensitive to the drug9,10. The gene discussed is MEN1; the disease is acute myeloid leukemia.